Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

DOI Full Paper Access

80

Citations

19

References

2020

Year

Ruth Perets, Jair Bar, Drew Rasco, Myung‐Ju Ahn, Kiyotaka Yoh, D.-W. Kim, Adnan Nagrial, Miyako Satouchi, Daniel Lee, David R. Spigel,

Annals of Oncology

Abstract

Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile among all quavonlimab doses/schedules evaluated; this regimen was the chosen RP2D.

References

	Year	Citations

Page 1